New drug cocktail shows promise for tough lung cancer

NCT ID NCT04526691

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a combination of two drugs—datopotamab deruxtecan (Dato-DXd) and pembrolizumab (Keytruda)—with or without standard chemotherapy in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 145 participants are enrolled, and researchers are monitoring side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (Keytruda) with or without platinum chemotherapy
What this could lead to: If successful, this combination could offer a new treatment option for advanced lung cancer that may shrink tumors or slow disease progression.
What could go wrong: This is an early Phase 1b trial with only 145 participants, so results are preliminary. Side effects from the drug combination could be significant, and the approach may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC NSCLC

Contacts and locations

Locations

(CIOCC-START) Hospital Universitario HM Sanchinarro

Madrid, 28050, Spain
Azienda Ospedaliera San Gerardo

Monza, 20052, Italy
Chung Shan Medical University Hospital

Taichung, 40201, Taiwan
City of Hope

Duarte, California, 91010, United States
H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO)

Barcelona, 08035, Spain
Hospital Puerta de Hierro

Majadahonda, 28222, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Instituto Europeo Di Oncologica

Milan, 20141, Italy
Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia

Naples, 80131, Italy
Johns Hopkins Kimmel Cancer Center

Washington D.C., District of Columbia, 20016, United States
Johns Hopkins Kimmel Cancer Center at Bayview

Baltimore, Maryland, 21224, United States
Mayo Clinic

Scottsdale, Arizona, 85259, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
National Cancer Center Hospital

Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Chiba, 277-8577, Japan
National Cheng Kung University Hospital NCKUH

Tainan, 704, Taiwan
National Taiwan University Hospital NTUH

Taipei, 100, Taiwan
Quantum Santa Fe

Santa Fe, New Mexico, 87505, United States
START Madrid - Hospital Universitario Fundacion Jimenez Diaz

Madrid, 28040, Spain
Showa Medical University Hospital

Tokyo, 142-8555, Japan
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
The Skip Viragh Outpatient Cancer Building

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.